Alimera Sciences Inc. (NASDAQ:ALIM) shares traded up 25.5% on Thursday . The company traded as high as $2.10 and last traded at $2.07, with a volume of 5,684,126 shares changing hands. The stock had previously closed at $1.65.

A number of research analysts have weighed in on the company. Cowen and Company reissued a “hold” rating on shares of Alimera Sciences in a report on Tuesday. Zacks Investment Research raised Alimera Sciences from a “sell” rating to a “hold” rating and set a $1.50 target price on the stock in a report on Wednesday, July 6th.

The company has a 50-day moving average of $1.41 and a 200-day moving average of $1.82. The company’s market cap is $93.35 million.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. The firm earned $5.80 million during the quarter, compared to analysts’ expectations of $5.83 million. During the same period last year, the firm posted ($0.27) earnings per share. The company’s quarterly revenue was up 48.7% on a year-over-year basis. On average, analysts expect that Alimera Sciences Inc. will post ($0.73) EPS for the current fiscal year.

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.